evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

5 questions · 5 findings · 1 reviews · Hepato-Biliary

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 5 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).

1 finding from 1 review

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).

1 finding from 1 review

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).

1 finding from 1 review

Pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care vs best supportive care

Disease progression · participants with advanced hepatocellular carcinoma

It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).

1 finding from 1 review